First Time Loading...

Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 1.93 USD -4.46% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. [ Read More ]

The intrinsic value of one CHRS stock under the Base Case scenario is 11.84 USD. Compared to the current market price of 1.93 USD, Coherus BioSciences Inc is Undervalued by 84%.

Key Points:
CHRS Intrinsic Value
Base Case
11.84 USD
Undervaluation 84%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Coherus BioSciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CHRS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Coherus BioSciences Inc

Provide an overview of the primary business activities
of Coherus BioSciences Inc.

What unique competitive advantages
does Coherus BioSciences Inc hold over its rivals?

What risks and challenges
does Coherus BioSciences Inc face in the near future?

Has there been any significant insider trading activity
in Coherus BioSciences Inc recently?

Summarize the latest earnings call
of Coherus BioSciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Coherus BioSciences Inc.

Provide P/S
for Coherus BioSciences Inc.

Provide P/E
for Coherus BioSciences Inc.

Provide P/OCF
for Coherus BioSciences Inc.

Provide P/FCFE
for Coherus BioSciences Inc.

Provide P/B
for Coherus BioSciences Inc.

Provide EV/S
for Coherus BioSciences Inc.

Provide EV/GP
for Coherus BioSciences Inc.

Provide EV/EBITDA
for Coherus BioSciences Inc.

Provide EV/EBIT
for Coherus BioSciences Inc.

Provide EV/OCF
for Coherus BioSciences Inc.

Provide EV/FCFF
for Coherus BioSciences Inc.

Provide EV/IC
for Coherus BioSciences Inc.

Show me price targets
for Coherus BioSciences Inc made by professional analysts.

What are the Revenue projections
for Coherus BioSciences Inc?

How accurate were the past Revenue estimates
for Coherus BioSciences Inc?

What are the Net Income projections
for Coherus BioSciences Inc?

How accurate were the past Net Income estimates
for Coherus BioSciences Inc?

What are the EPS projections
for Coherus BioSciences Inc?

How accurate were the past EPS estimates
for Coherus BioSciences Inc?

What are the EBIT projections
for Coherus BioSciences Inc?

How accurate were the past EBIT estimates
for Coherus BioSciences Inc?

Compare the revenue forecasts
for Coherus BioSciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Coherus BioSciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Coherus BioSciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Coherus BioSciences Inc compared to its peers.

Compare the P/E ratios
of Coherus BioSciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Coherus BioSciences Inc with its peers.

Analyze the financial leverage
of Coherus BioSciences Inc compared to its main competitors.

Show all profitability ratios
for Coherus BioSciences Inc.

Provide ROE
for Coherus BioSciences Inc.

Provide ROA
for Coherus BioSciences Inc.

Provide ROIC
for Coherus BioSciences Inc.

Provide ROCE
for Coherus BioSciences Inc.

Provide Gross Margin
for Coherus BioSciences Inc.

Provide Operating Margin
for Coherus BioSciences Inc.

Provide Net Margin
for Coherus BioSciences Inc.

Provide FCF Margin
for Coherus BioSciences Inc.

Show all solvency ratios
for Coherus BioSciences Inc.

Provide D/E Ratio
for Coherus BioSciences Inc.

Provide D/A Ratio
for Coherus BioSciences Inc.

Provide Interest Coverage Ratio
for Coherus BioSciences Inc.

Provide Altman Z-Score Ratio
for Coherus BioSciences Inc.

Provide Quick Ratio
for Coherus BioSciences Inc.

Provide Current Ratio
for Coherus BioSciences Inc.

Provide Cash Ratio
for Coherus BioSciences Inc.

What is the historical Revenue growth
over the last 5 years for Coherus BioSciences Inc?

What is the historical Net Income growth
over the last 5 years for Coherus BioSciences Inc?

What is the current Free Cash Flow
of Coherus BioSciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Coherus BioSciences Inc.

Financials

Balance Sheet Decomposition
Coherus BioSciences Inc

Current Assets 508.4m
Cash & Short-Term Investments 117.7m
Receivables 260.5m
Other Current Assets 130.1m
Non-Current Assets 121.2m
Intangibles 71.7m
Other Non-Current Assets 49.6m
Current Liabilities 169.6m
Accrued Liabilities 169.6m
Non-Current Liabilities 653.4m
Long-Term Debt 473.4m
Other Non-Current Liabilities 180m
Efficiency

Earnings Waterfall
Coherus BioSciences Inc

Revenue
257.2m USD
Cost of Revenue
-159m USD
Gross Profit
98.3m USD
Operating Expenses
-301.5m USD
Operating Income
-203.2m USD
Other Expenses
-34.7m USD
Net Income
-237.9m USD

Free Cash Flow Analysis
Coherus BioSciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CHRS Profitability Score
Profitability Due Diligence

Coherus BioSciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROE
ROE is Increasing
Exceptional Revenue Growth Forecast
28/100
Profitability
Score

Coherus BioSciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

CHRS Solvency Score
Solvency Due Diligence

Coherus BioSciences Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
47/100
Solvency
Score

Coherus BioSciences Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CHRS Price Targets Summary
Coherus BioSciences Inc

Wall Street analysts forecast CHRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CHRS is 10.64 USD with a low forecast of 4.04 USD and a high forecast of 24.15 USD.

Lowest
Price Target
4.04 USD
109% Upside
Average
Price Target
10.64 USD
451% Upside
Highest
Price Target
24.15 USD
1 151% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CHRS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CHRS Price
Coherus BioSciences Inc

1M 1M
-16%
6M 6M
-30%
1Y 1Y
-74%
3Y 3Y
-87%
5Y 5Y
-88%
10Y 10Y
-85%
Annual Price Range
1.93
52w Low
1.59
52w High
8.14
Price Metrics
Average Annual Return -10.15%
Standard Deviation of Annual Returns 27.71%
Max Drawdown -93%
Shares Statistics
Market Capitalization 214.9m USD
Shares Outstanding 111 364 000
Percentage of Shares Shorted 24.88%

CHRS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Coherus BioSciences Inc Logo
Coherus BioSciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

214.9m USD

Dividend Yield

0%

Description

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.

Contact

CALIFORNIA
Redwood City
333 Twin Dolphin Dr Ste 600
+16506493530.0
https://www.coherus.com/

IPO

2014-11-06

Employees

332

Officers

Chairman, President & CEO
Mr. Dennis M. Lanfear
Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller
Mr. Bryan J. McMichael
Chief Technical Officer
Mr. Richard L. Hameister
Vice President of Investor Relations
Ms. Jami Taylor
Vice President of Communications
Cheston Turbyfill
Executive Vice President of Corporate Development
Mr. Scott Saywell
Show More
Chief Human Resources Officer
Ms. Rebecca Sunshine
Senior Vice President of Commercial Analytics & Trade
Mr. Michael Chen
Chief Commercial Officer
Mr. Paul Reider
Chief Development Officer & Chairman of Scientific Advisory Board
Dr. Theresa M. Lavallee Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CHRS stock?

The intrinsic value of one CHRS stock under the Base Case scenario is 11.84 USD.

Is CHRS stock undervalued or overvalued?

Compared to the current market price of 1.93 USD, Coherus BioSciences Inc is Undervalued by 84%.